# Clinical Cases: Vaccines and Immunopharmacology

## Case 1: Vaccine-Preventable Disease in Unvaccinated Child

### Patient Presentation
**Demographics:** 4-year-old male

**Chief Complaint:** High fever and rash for 3 days

**History of Present Illness:**
The patient developed high fever (40C) 3 days ago followed by cough, coryza (runny nose), and conjunctivitis. Yesterday a rash appeared on his face and has spread down his trunk. His mother reports he has not received any childhood vaccinations due to parental concerns about vaccine safety.

**Vaccination History:**
- No vaccines received (parental exemption)

**Social History:**
- Attends daycare
- Recent outbreak of measles in community

**Physical Examination:**
- Temperature: 39.8C
- Heart rate: 130 bpm
- General: Ill-appearing, irritable
- Eyes: Bilateral conjunctival injection
- Mouth: Koplik spots on buccal mucosa (white spots opposite molars)
- Skin: Erythematous maculopapular rash beginning on face, spreading to trunk
- Lungs: Clear
- Lymph nodes: Cervical lymphadenopathy

### Workup and Results

**Laboratory Studies:**
- WBC: 3,800/mcL (leukopenia common in measles)
- Measles IgM: Positive
- Measles IgG: Negative
- Measles PCR (nasopharyngeal swab): Positive

### Clinical Image

![Measles Rash and Koplik Spots](case_01_image.jpg)

*Clinical photograph demonstrating characteristic measles presentation with erythematous maculopapular rash and inset showing Koplik spots on buccal mucosa - pathognomonic for measles.*

### Diagnosis
**Measles (Rubeola) in Unvaccinated Child**

Classic presentation:
- Prodrome: Fever, cough, coryza, conjunctivitis (3 C's)
- Koplik spots (pathognomonic)
- Maculopapular rash spreading cephalocaudally

### Discussion
This case illustrates vaccine-preventable disease:

- **Herd Immunity Threshold**: The lecture describes how measles has an R0 of 12-18, requiring 92-95% population immunity for herd protection. Unvaccinated individuals are protected only when this threshold is maintained.

- **MMR Vaccine**: The lecture explains that MMR is a live attenuated vaccine typically given at 12-15 months with a second dose at 4-6 years. Two doses provide 97% immunity against measles.

- **Immunological Memory**: The lecture emphasizes that vaccines work by exploiting immunological memory. Memory B and T cells generated during vaccination mount rapid, robust responses upon natural exposure.

- **Live Vaccine Characteristics**: Live attenuated vaccines like MMR generally require only one or two doses, induce strong cellular and humoral immunity, but are contraindicated in immunocompromised patients.

### Treatment Plan
1. **Supportive Care:**
   - Antipyretics for fever
   - Adequate hydration
   - Vitamin A supplementation (reduces complications and mortality)

2. **Isolation:**
   - Airborne precautions (negative pressure room)
   - Contagious from 4 days before to 4 days after rash onset
   - Exclude from daycare until non-infectious

3. **Contact Tracing:**
   - Notify public health department
   - Post-exposure prophylaxis for susceptible contacts
   - MMR vaccine within 72 hours or immunoglobulin within 6 days

4. **Monitoring for Complications:**
   - Otitis media
   - Pneumonia (most common cause of death)
   - Encephalitis
   - SSPE (rare, late complication)

5. **Family Counseling:**
   - Discuss importance of completing vaccination series after recovery
   - Address vaccine concerns with evidence-based information

### Teaching Points
1. Measles requires 92-95% population immunity for herd protection (R0 12-18)
2. MMR vaccine provides 97% protection with two doses
3. Live attenuated vaccines are contraindicated in immunocompromised patients
4. Koplik spots are pathognomonic for measles
5. Vitamin A supplementation reduces measles complications

---

## Case 2: Biologics and Immunosuppression Complications

### Patient Presentation
**Demographics:** 62-year-old female

**Chief Complaint:** Night sweats, weight loss, and chronic cough for 2 months

**History of Present Illness:**
The patient has rheumatoid arthritis treated with adalimumab (anti-TNF-alpha) for the past 3 years with excellent disease control. Over the past 2 months, she has developed progressive fatigue, night sweats, unintentional weight loss (15 pounds), and productive cough. She recalls her TB screening was negative before starting adalimumab.

**Past Medical History:**
- Rheumatoid arthritis (10 years)
- Osteoporosis
- Former smoker (30 pack-years, quit 5 years ago)

**Medications:**
- Adalimumab 40 mg every 2 weeks
- Methotrexate 15 mg weekly
- Folic acid 1 mg daily
- Alendronate 70 mg weekly

**Physical Examination:**
- Temperature: 37.8C (low-grade fever)
- Weight: 58 kg (down from 65 kg)
- General: Cachectic appearance
- Lungs: Right upper lobe crackles
- Lymph nodes: Right supraclavicular lymphadenopathy

### Workup and Results

**Laboratory Studies:**
- WBC: 6,200/mcL
- Hemoglobin: 10.8 g/dL
- ESR: 78 mm/hr
- CRP: 45 mg/L
- HIV: Negative

**Chest X-ray:**
- Right upper lobe infiltrate with cavitation

**Sputum Studies:**
- AFB smear: Positive for acid-fast bacilli
- TB PCR: Positive for Mycobacterium tuberculosis

**Prior Records:**
- TB skin test (before adalimumab): 4 mm (negative)
- QuantiFERON-TB Gold: Not performed

### Clinical Image

![Reactivation TB](case_01_image.jpg)

*Chest X-ray demonstrating right upper lobe cavitary lesion consistent with pulmonary tuberculosis. This classic presentation occurs with reactivation TB, which is increased in patients on TNF-alpha inhibitors.*

### Diagnosis
**Reactivation Pulmonary Tuberculosis in Setting of TNF-alpha Inhibitor Therapy**

Risk factors:
- Anti-TNF therapy (adalimumab)
- Possible latent TB with false-negative initial screening
- Former smoker

### Discussion
This case illustrates immunosuppression risks:

- **TB Screening Requirement**: The lecture emphasizes that patients must be screened for latent tuberculosis before starting TNF inhibitor therapy. TNF-alpha is essential for granuloma formation and TB containment.

- **TNF Inhibitor Mechanism**: The lecture describes how TNF inhibitors block the pro-inflammatory cytokine TNF-alpha, providing benefit in autoimmune diseases but impairing host defense against intracellular pathogens, particularly mycobacteria.

- **Screening Limitations**: TST can have false negatives in immunocompromised patients. The lecture notes that interferon-gamma release assays (IGRAs) like QuantiFERON may be more sensitive in this setting.

- **Reactivation Risk**: Anti-TNF therapy increases TB risk 2-8 fold, with most cases occurring in the first year but risk persisting throughout therapy.

### Treatment Plan
1. **Discontinue Adalimumab:**
   - Stop immediately
   - Do not restart until TB adequately treated

2. **TB Treatment:**
   - Standard 4-drug regimen (RIPE: rifampin, isoniazid, pyrazinamide, ethambutol)
   - Duration: 6-9 months minimum
   - Directly observed therapy recommended

3. **RA Management:**
   - Consider alternative non-biologic DMARDs during TB treatment
   - Avoid all TNF inhibitors
   - Rituximab (anti-CD20) may be safer alternative after TB treated

4. **Contact Investigation:**
   - Household contact screening
   - Report to public health

5. **Future Considerations:**
   - If TNF inhibitor ever reconsidered, complete full TB treatment first
   - Repeat LTBI screening before any future biologic

### Teaching Points
1. Screen for latent TB before starting TNF inhibitors (TST or IGRA)
2. TNF-alpha is essential for granuloma formation and TB containment
3. TNF inhibitor-associated TB is usually reactivation, not primary infection
4. Anti-TNF therapy increases TB risk 2-8 fold
5. Treat latent TB infection before starting TNF inhibitors

---

## Case 3: Adverse Event Following mRNA Vaccination

### Patient Presentation
**Demographics:** 19-year-old male

**Chief Complaint:** Chest pain 4 days after second COVID-19 vaccine dose

**History of Present Illness:**
The patient received his second dose of an mRNA COVID-19 vaccine 4 days ago. He developed chest pain yesterday that is sharp, worse with inspiration and lying flat, and improved by sitting forward. He also has low-grade fever and fatigue. He denies shortness of breath at rest.

**Past Medical History:**
- No significant medical history
- No prior cardiac disease
- Healthy, active college athlete

**Physical Examination:**
- Blood pressure: 118/72 mmHg
- Heart rate: 88 bpm
- Temperature: 37.6C
- General: Mildly uncomfortable
- Cardiac: Regular rhythm, no murmur, possible pericardial friction rub
- Lungs: Clear

### Workup and Results

**Laboratory Studies:**
- Troponin I: 2.4 ng/mL (elevated, normal <0.04)
- BNP: 180 pg/mL (mildly elevated)
- CRP: 68 mg/L (elevated)
- WBC: 9,800/mcL

**ECG:**
- Diffuse ST elevation
- PR depression
- No reciprocal changes

**Echocardiogram:**
- Mild left ventricular dysfunction (EF 50%)
- Small pericardial effusion
- No regional wall motion abnormalities

**Cardiac MRI:**
- Subepicardial late gadolinium enhancement
- Myocardial edema
- Consistent with acute myocarditis

### Clinical Image

![Myocarditis MRI](case_01_image.jpg)

*Cardiac MRI demonstrating myocarditis with subepicardial late gadolinium enhancement (arrows) and myocardial edema, findings consistent with vaccine-associated myocarditis. Note the characteristic non-ischemic pattern.*

### Diagnosis
**mRNA COVID-19 Vaccine-Associated Myopericarditis**

Features:
- Temporal relationship (within 7 days of dose 2)
- Characteristic demographic (young male)
- Typical presentation and imaging findings

### Discussion
This case illustrates vaccine adverse events:

- **Myocarditis Epidemiology**: The lecture notes that myocarditis following mRNA COVID-19 vaccines is most commonly reported in young males after the second dose. Incidence is approximately 1 in 50,000 in this demographic.

- **Risk-Benefit Analysis**: The lecture emphasizes that the risk of myocarditis from COVID-19 infection is significantly higher than from vaccination. Most vaccine-associated myocarditis cases are mild and resolve completely.

- **Vaccine Safety Monitoring**: The lecture describes passive surveillance systems (VAERS) and active surveillance that detect rare adverse events not seen in clinical trials. This allowed rapid identification of the myocarditis signal.

- **True Contraindications**: The lecture distinguishes true contraindications (prior severe allergic reaction to vaccine component) from precautions. Prior myocarditis after mRNA vaccine is a precaution for future mRNA doses.

### Treatment Plan
1. **Acute Management:**
   - Hospital admission for monitoring
   - Telemetry
   - NSAIDs (ibuprofen) for inflammation
   - Colchicine may be added
   - Restrict physical activity

2. **Monitoring:**
   - Serial troponins until trending down
   - Repeat echocardiogram before discharge
   - Cardiac MRI at 3-6 months

3. **Activity Restriction:**
   - No competitive sports for 3-6 months
   - Gradual return to activity after cardiac clearance

4. **Prognosis:**
   - Majority recover fully within weeks to months
   - Repeat imaging to confirm resolution

5. **Future Vaccination:**
   - Counsel about precaution with future mRNA vaccines
   - Consider different vaccine platform if boosters needed
   - Discuss with cardiology

### Teaching Points
1. Vaccine-associated myocarditis is rare but most common in young males after mRNA vaccine
2. Anaphylaxis from vaccines occurs in approximately 1 per million doses
3. VAERS is a passive surveillance system accepting reports from anyone
4. True vaccine contraindication is severe allergic reaction to a vaccine component
5. Most vaccine-associated myocarditis cases are mild and resolve completely

---

## Image Reference

For visual reference of vaccine and immunopharmacology concepts, see:
- Radiopaedia: [Myocarditis](https://radiopaedia.org/articles/myocarditis) - Cardiac MRI findings
- Wikipedia: [Vaccination](https://en.wikipedia.org/wiki/Vaccination) - Immunological principles
- Radiopaedia: [Tuberculosis](https://radiopaedia.org/articles/pulmonary-tuberculosis) - Reactivation patterns

---

## Learning Points

1. **Herd Immunity Threshold**: Depends on R0; measles (R0 12-18) requires 92-95% immunity

2. **TB Screening Before TNF Inhibitors**: Mandatory; TNF essential for granuloma formation

3. **Vaccine Adverse Events**: Anaphylaxis ~1/million; myocarditis rare but real signal with mRNA vaccines

4. **Live Vaccine Contraindications**: Immunocompromised patients, pregnancy

5. **Memory Response**: Vaccines exploit immunological memory for rapid, robust response on re-exposure